Catalyst overview
Research summary
This catalyst tracks a Approved update for MYQORZO (Aficamten) in Obstructive hypertrophic cardiomyopathy (oHCM). The expected timing is based on the latest available company guidance and may change.
08/06/26:- Q2 MYQORZO net revenue was $25.3M; Germany launched; United Kingdom approved.
Verification
Confirm timing and program details against the company announcement or filing.